Accretion®
Nutraveda Limited
Formerly known as Accretion Nutraveda Private Limited

Date: 03rd November, 2026

To,
Corporate Relations Department
BSE Limited
25th Floor, P J Towers,
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 544694

Dear Sir/ Madam,

Subject: Investors/ Analysts Presentation for the half year ended on 30th September, 2026

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith Investors/ Analysts presentation for the half year ended on 30th September, 2026.

The presentation shall also be made available at Company's website www.accretionnutraveda.com.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Nutraveda Limited
[Formerly Known as Accretion Nutraveda Private Limited]

PAYAL HARESHBHAI KOTADIYA
Digitally signed by PAYAL HARESHBHAI KOTADIYA
Date: 2026.11.03 17:54:21 +05'30'

CS Payal Kotadiya
Company Secretary and Compliance Officer

Encl: as above



Accretion®
Nutraveda Limited

ACCRETION NUTRAVEDA LIMITED

INVESTOR P R E S E N TAT I O N H1 FY 2027

DISCLAIMER

This presentation contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Accretion Nutraveda Limited (ANL) and its group companies’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, government and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Accretion Nutraveda Limited undertakes no obligation to periodically revise any forward-looking statements to reflect future/likely events or circumstances.



TABLE OF CONTENTS



Company Overview

Shareholding Overview

Business Overview

Industry Overview

Financial Highlights

Way Ahead



Accretion®
Nutraveda Limited

COMPANY OVERVIEW

ACCRETION NUTRAVEDA LIMITED AT A GLANCE

Science-Driven Nutrition | Wellness-Focused Growth

Incorporated on 16th March 2021, Accretion Nutraveda Limited is engaged in the manufacturing of Ayurvedic, Nutraceutical and wellness products, catering to diverse healthcare and wellness needs through a portfolio of tablets, capsules, liquids, powders/Churans/Avleh, oils and other oral and external preparations. The Company is supported by an experienced management team and manufacturing infrastructure designed to facilitate efficient operations and consistent product quality.

With a focus on manufacturing excellence, product diversification and regulatory compliance, the Company serves both domestic and international markets. Its manufacturing and quality systems are supported by various certifications and licences, including WHO-GMP, GMP Certificate, FSSAI License, FSSC 22000, ISO 9001:2015, ISO 45001:2018 and Halal certification.

VISION

To be a globally trusted healthcare Company empowering healthier lives through innovative, high-quality healthcare solutions, blending traditional wellness with modern science to create a healthier and sustainable future.

MISSION

To deliver safe, effective, and innovative healthcare solutions driven by quality, integrity, affordability, and product-centric excellence while focusing on continuous innovation, operational excellence, and sustainable growth.







PUBLIC LISTING – A NEW CHAPTER OF GROWTH

Accretion Nutraveda Limited successfully launched its Initial Public Offering (IPO) in February 2026 and marked its debut on the BSE SME Platform of BSE Limited, reflecting a significant milestone in the Company's growth journey. The IPO raised ₹ 24.77 crore through the issuance of 19.20 lakh equity shares and received an encouraging response from investor The Company further witnessed a strong stock market debut, listing at an impressive premium of nearly 50%, highlighting robust investor confidence in its business fundamentals, growth strategy, and long-term potential.

KEY MILESTONES

2021


- Incorporated as “Accretion Nutraveda Private Limited” on 16th March, 2021 under the Companies Act, 2013
- Received Certificate for Good Manufacturing Practices (GMP) for manufacturing Ayurveda, Siddha & Unani Drugs on 01st September, 2021
- Established a strong foundation in Ayurvedic & Nutraceutical manufacturing with a focus on quality and compliance.

2025


- Converted from Private Limited to Public Limited Company and renamed as “Accretion Nutraveda Limited” effective 02nd May, 2025
- Achieved ISO 9001:2015 certification for Quality Management Systems.
- Received ISO 45001:2018 certification for Occupational Health & Safety Management Systems.
- Awarded WHO-GMP certification strengthening global quality standards and manufacturing excellence
- Obtained FSSC 22000 certification and Halal Certification Scheme approval on 11th July, 2025.
- Received FSSAI License and Registration Cum Membership Certificate (RCMC), enhancing domestic and export business capabilities
- Certified under Legal Metrology (Packaged Commodities) Rules, 2011 as Manufacturer & Packer

2026

- Successfully listed on the BSE SME Platform of BSE Limited in 04th February 2026, marking a significant milestone in the Company’s growth journey and strengthening its presence in the capital markets.
- Received Global Export Excellence Award in Ayurvedic & Nutraceutical Manufacturing at the “Leaders of Navbharat Awards & Conclave" organized by the Times Now Group.









Accretion®
Nutraveda Limited


SHAREHOLDING OVERVIEW

SHAREHOLDING PATTERN AS ON 30th SEPTEMBER 2026

Accretion® Nutraveda Limited

Script code of Company at BSE SME platform of BSE Limited (BSE SME)	544694		
Category of Investor	30th September, 2026		
	No. of Shareholders	No. of Shares Held	Holding (%)
Promoter & Promoter Group	10	5320000	73.48 %
Public Holding	370	1920000	26.52 %
Total	380	7240000	100.00 %

Stock Information as on 30th September, 2026	
Share Price on BSE SME Platform	₹ 305.00
52 Week High	₹ 313.00
52 Week Low	₹ 150.10
Marker Capitalisation	₹ 213.58 Crore
Index	BSE SME IPO
Basic Industry	Pharmaceuticals





Accretion®
Nutraveda Limited

BUSINESS OVERVIEW

BPHARM TO BSE SME PLATFORM OF BSE LIMITED

Accretion® Nutraveda Limited

United by a common vision and a strong foundation in Pharmacy Classroom, six B.Pharm college friends embarked on an entrepreneurial journey that led to the establishment of Accretion Nutraveda Limited. Through shared ambition, professional expertise and collective determination, the Company has progressed to become listed on the BSE SME Platform of BSE Limited. The promoters continue to lead the Company with a focus on business development, innovation and creating sustainable value for all stakeholders.



MAYUR SOJITRA

Promoter &
Managing Director

- B.Pharm
- M.B.A
- 14+ years
- Expertise in strategic planning, business management and international business.



HARSHAD RATHOD

Promoter, Chairman
Non-Executive Director

- B.Pharm
- M.B.A
- 16+ years
- Expertise in Business Development, Growth Strategy & Marketing.



PARASKUMAR PARMAR

Promoter,
Executive Director
& CFO

- B.Pharm
- M.A
- 15+ years
- Expertise in Financial Management, Strategic Planning & Risk Management.



ANKURKUMAR PATEL

Promoter &
Whole time Director

- B.Pharm
- M.Pharm (Ayurved)
- 16+ years
- Expertise in formulation development Quality systems & Operational management.



VIVEK PATEL

Promoter &
Non- Executive Director

- B.Pharm
- 16+ years
- M.B.A
- Expertise in across Production, Marketing, Logistics & Business Operations.



HARDIK PRAJAPATI

Promoter &
Non- Executive Director

- B.Pharm
- M.Pharm
- 16+ years
- Expertise in Production Management, Technical Operations & Manufacturing Processes.

"Six Minds, One Mission — Shaping the Future of healthcare."

OUR BUSINESS MODEL

Accretion Nutraveda Limited(ANL) follows a diversified business model encompassing CDMO Services, own-brand sales and exports, and product development and technology transfer. These business verticals support the Company's manufacturing operations, market presence and opportunities for business expansion.

1. CDMO SERVICES

ANL provides operational partnership to domestic and international clients in the Ayurvedic, Nutraceutical and Wellness sector Its capabilities cover product development, formulation scale-up and commercial manufacturing across multiple dosage forms, supported by established quality control processes and applicable regulatory standards. This vertical enables the Company to cater to client-specific requirements while utilising its manufacturing capabilities

2. OWN BRAND EXPORTS

The Company undertakes the marketing and sale of its own-brand healthcare formulations across domestic and international markets. Its diverse product portfolio and distribution relationships support market development, brand visibility and access to a wider customer base. The Company continues to explore opportunities to expand its product reach and strengthen its presence across relevant markets.

3. LICENSING / PRODUCT DEVELOPMENT

The Company focuses on product development and formulation-related capabilities to address evolving market requirements. Its activities may include formulation development, technology transfer, process scale-up and manufacturing support based on business partner requirements. Licensing of developed product dossiers and related technical documentation, where applicable, can further support partners in product registration and market entry.

PRODUCT BY DOSAGE FORMS

Accretion®
Nutraveda Limited



TABLETS



CAPSULES



ORAL LIQUIDS



EXTERNAL PREPARATIONS



ORAL POWDER



OILS

THERAPEUTIC SEGMENT

Accretion® Nutraveda Limited

- Brain, Memory & Neuron Care
- UTI Care
- Cardiac Care
- Liver Care
- Protein Supplements
- Pediatric Care
- Gastrointestinal (GIT) Care



- Aphrodisiac & Vitality Care
- Digestive Care
- Urinary Tract Care
- Systemic & General Wellness
- Baby Care
- Pain Relief & Nasal Care
- Single Herb Formulations



- Effervescent Formulations
- Joint & Bone Care
- Immunity Booster
- Gynec Care
- Hair, Skin & Nail Care
- Infertility & PCOS Care
- Respiratory Care



ADVANCED MANUFACTURING INFRASTRUCTURE

Dosage	Installed Capacity (in Numbers / Bottles / Tube / Bottle & Pouch)
Tablets (in Numbers)	36.50 Mn
Capsules (in Numbers)	17.50 Mn
Oral Liquid (in Bottles)	1.825 Mn
External Preparation (in Numbers & Tube)	10.65 Mn
Oral Powders / Churans (in Bottle and Pouch)	4.075 Mn
Oils (in Bottle)	1.095 Mn
Total (All Categories)	71.645 Mn Total Installed Capacity





Accretion®
Nutraveda Limited

INDUSTRY OVERVIEW

INDIA : WELLNESS & NUTRACEUTICAL HUB OF THE WORLD

Accretion® Nutraveda Limited

India's Nutraceutical Industry – A Fast-Growing Global Wellness Market

India's nutraceutical market is estimated at US$37–38 billion in 2026 and projected to reach US$55–57 billion by 2030, at an estimated CAGR of 10.5%.

Expanding Market Opportunities

Rising demand for dietary supplements, functional foods, immunity and preventive healthcare is driving industry growth.


India's Strong Ayurveda Heritage

India's rich Ayurvedic heritage and growing global demand for herbal and plant-based wellness products offer significant growth opportunities.

Strengthening Global Export Presence

India's AYUSH and herbal exports reached US$638.71 million in FY26, with Ayurvedic products reaching 150 countries worldwide.


Indian Nutraceutical Market (US$ Billion)



Growth Drivers

- *Rising preventive healthcare awareness*
- *Increasing lifestyle disorders & immunity concerns*
- *Growth in fitness and wellness culture*
- *Expansion of e-commerce and digital healthcare platforms*
- *Increasing demand for herbal and clean-label products*
- *Government support towards AYUSH and wellness sectors*
- *Growing export opportunities for Indian nutraceutical products*

Global Nutraceutical Market (US$ Billion)



Indian Ayurveda & Herbal Market (US$ Billion)



- Sources: Care Edge Ratings, Grand View Research, ASSOCHAM, TechSci Research, IBEF, NITI Aayog, Ministry of AYUSH.

CDMO INDUSTRY OVERVIEW

Accretion® Nutraveda Limited

GLOBAL CDMO INDUSTRY

Role & Importance of CDMOs

End-to-end services from drug development to commercial production, helping pharma firms cut costs, scale faster, and access advanced technologies.

Key Market Drivers

Growing demand for biologics, increased outsourcing, rising R&D investments and strategic partnerships.

Emerging Market Trends

Shift towards integrated CDMO services, advanced manufacturing technologies, digitalization and sustainable operations.

Challenges

- *Strict FDA, EMA GMP regulations leading to higher costs and delays*
- *Fragmented market with strong competition from small & mid-sized players*

Regional Insights

- **North America:** *Largest regional market, supported by established CDMO infrastructure and pharmaceutical R&D.*
- **Asia-Pacific (including India):** Fastest-growing region, driven by cost competitiveness, manufacturing expansion and rising investments.

Market Size & Growth Outlook

- *Valued at USD 214.95 billion in 2026.*
- *Projected to reach USD 419.93 billion by 2034.*
- *Growing at a CAGR of 8.7%*

INDIAN CDMO INDUSTRY

India's CDMO manufacturing market is estimated to grow from USD 29.53 billion in 2026 to USD 57.94 billion by 2031, at a CAGR of 14.43%, strengthening India's position as a preferred global pharmaceutical manufacturing and outsourcing destination.

Key Drivers of Growth

- *Rising demand for dietary supplements, functional foods and wellness products.*
- *Increasing innovation in customised nutraceutical formulations.*
- *Growing global acceptance of Ayurveda and herbal products.*
- *Rising outsourcing by nutraceutical and wellness brands.*
- *Investments in manufacturing infrastructure, automation and R&D.*
- *Expanding domestic and international market opportunities.*



Accretion®
Nutraveda Limited

FINANCIAL HIGHLIGHTS

A MESSAGE FROM OUR LEADERSHIP



H1 FY 2026–27 has been an important period for Accretion Nutraveda Limited(ANL) as the Company continues to focus on Business expansion and operational efficiency. The Company Recorded revenue of ₹ 29.44 crore, representing a year-on-year growth of 109.35%. EBITDA stood at ₹ 6.26 crore, registering a growth of 88.03%, while Profit After Tax (PAT) increased by 98.66%. The performance reflects the Company's progress across its nutraceutical, Ayurvedic and wellness product segments, supported by its focus on product diversification, manufacturing efficiency and expanding market opportunities.

Looking ahead, the Company aims to strengthen its manufacturing capabilities through capacity expansion, additional machinery and greater automation. The planned utilisation of IPO proceeds, in accordance with the stated objects, is intended to support improvements and position the Company to address emerging opportunities in the healthcare markets.

With a continued focus on product quality, innovation and regulatory compliance, the Company seeks to expand its market presence and build enduring relationships with business partner The Company remains committed to responsible business practices and sustainable growth, with the objective of creating long-term value for shareholders and other stakeholders.

"Inspired by Nature. Guided by Science. Focused on Health & Wellness"



Accretion®
Nutraveda Limited

PERFORMANCE HIGHLIGHT (H1 FY 2027)

TOTAL INCOME - ₹ 29.44 Cr

(109.35% YoY)

EBITDA - ₹ 6.26 Cr

(88.03%% YoY)

PAT - ₹ 4.73 Cr

(98.66% YoY)

PROFIT AND LOSS STATEMENT

Particulars (₹ in Crore)	H1 FY27	H1 FY26	YoY%	H2 FY26	FY26
Total Income from Operations	**29.44**	**14.06**	**109.35%**	**19.54**	**33.6**
Other Income	0.16	0.00		0.11	0.11
Total Income	**29.6**	**14.07**	**110.38%**	**19.65**	**33.71**
Raw Materials	21.68	9.57		14.53	24.1
Employee Cost	0.64	0.37		0.69	1.07
Other Expenses	1.37	0.79		0.75	1.54
Total Expenditure	**23.69**	**10.73**	**120.78%**	**15.97**	**26.71**
EBITDA*	**6.26**	**3.33**	**88.03%**	**3.68**	**7**
EBIDTA Margin* (%)	**21.27**	**23.67%**	**(241 Bps)**	**18.81%**	**20.85 %**
Depreciation	0.17	0.16		0.1	0.26
Interest	0.41	0.26		0.27	0.53
Exceptional Item (Gain) / Loss	0	0		0	0
Profit Before Tax	**5.69**	**2.91**	**95.53%**	**3.3**	**6.21**
Tax	0.96	0.53		0.61	1.14
Profit After Tax	**4.73**	**2.38**	**98.66%**	**2.69**	**5.07**
Profit After Tax Margin%	**16.06%**	**16.92%**	**(86 Bps)**	**13.76%**	**15.08 %**
EPS (In ₹)	**6.53**	**4.83**	**35.20%**	**4.53**	**9.35**

FINANCIAL PERFORMANCE HIGHLIGHTS HI FY2027

Revenue in H1 FY27 stood at ₹ 29.44 crore, up 109.35% YoY, driven by increased demand for healthcare products, a diversified product portfolio and wider market reach.


EBITDA grew 88.03% YoY to ₹ 6.26 crore, with an EBITDA margin of 21.27%, supported by strong revenue growth, higher sales volumes and effective cost management, while continuing to invest in manpower and business development initiatives.

PAT increased 98.66% YoY to ₹ 4.73 crore, with a PAT margin of 16.06%, driven by strong revenue growth, improved operational efficiencies and effective cost control.


FINANCIAL HIGHLIGHTS – HALF YEARLY (HI FY27)

Accretion® Pharmaceuticals Limited


Revenue (₹ Cr)




EBITDA* (₹ Cr) / Margin (%)



PAT (₹ Cr) / Margin (%)




Net Worth (₹ Cr)




FINANCIAL HIGHLIGHTS – ANNUALLY (FY26)

Accretion Pharmaceuticals Limited


Revenue (₹ Cr)




EBITDA* (₹ Cr) / Margin (%)



PAT (₹ Cr) / Margin (%)



Net Worth (₹ Cr)





Accretion®
Nutraveda Limited

THE WAY AHEAD

THE WAY AHEAD

Accretion® Nutraveda Limited

CAPEX

The Company aims to enhance its manufacturing capabilities through the addition of leased premises adjacent to its existing facility, along with investments in machinery and equipment. The proposed expansion will focus on increasing production capacity, improving automation, strengthening operational efficiency and meeting growing business requirements

PRODUCT PORTFOLIO EXPANSION

The Company plans to expand its Ayurvedic and nutraceutical product range by introducing new formulations across tablets, capsules, liquids, powders, oils and external preparations. The focus will remain on developing products in line with evolving consumer preferences and emerging healthcare requirements.

OWN BRAND DEVELOPMENT

The Company intends to strengthen its own-brand business through new product launches, focused marketing initiatives and wider market reach. These efforts will help enhance brand visibility, increase customer engagement and build diversified revenue streams.

INTERNATIONAL MARKET EXPANSION

The Company will continue to explore opportunities in new international markets by pursuing relevant product registrations, regulatory compliances and export partnerships. Expanding its geographical reach will help broaden its customer base and strengthen its export business.

STRATEGIC PARTNERSHIPS AND DISTRIBUTION NETWORK

The Company aims to strengthen its business network by building relationships with domestic and international customers, distributors, merchant exporters and contract manufacturing partners These associations will support wider market access, business development and sustainable growth.



LISTED ON BSE SME PLATFORM

Accretion® Nutraveda Limited

THANK YOU.

ACCRETION NUTRAVEDA LIMITED
CS Payal Kotadiya
Company Secretary & Compliance Officer
E-mail: compliance@accretionnutraveda.com
www.accretionnutraveda.com